A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE

计划入组 36 人

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE

计划入组 19 人

A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED,PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OFMASITINIB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE

计划入组 1 人

Alzheimer’s disease(AstronauTx)

Erbb2 inhibitors (Alzheimer’s disease)

INmune Bio

United States

Annexon

United States

Lexeo Therapeutics

United States

Axsome Therapeutics Announces Successful Completion of Phase 3 Clinical Trial for Alzheimer’s Disease Agitation

European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease

Cognito Therapeutics Showcases Early-Stage Cost-Effectiveness of Spectris Therapy for Alzheimer’s Disease